Using PEEL-224 with Vincristine and Temozolomide for Pediatric Solid Tumors

A Phase 1/2 Clinical Trial of the Novel Topoisomerase I Inhibitor PEEL-224 as a Single Agent and in Combination With Vincristine and Temozolomide in Children With Refractory, Progressive or Relapsed Solid Tumors

This study is testing a new treatment called PEEL-224, alone and with other drugs, to see if it can help children with tough-to-treat solid tumors like neuroblastoma and rhabdomyosarcoma.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 59 (estimated)
• Ages: 1 Year to 30 Years
• Sex: All
• Sponsor: Children's Hospital of Philadelphia (Academic / other)
• Drugs / interventions: chemotherapy, radiation
• Locations: 7 sites (Los Angeles, California and 6 other locations)
• Trial ID: NCT06721689 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to evaluate the safety and effectiveness of PEEL-224, both as a standalone treatment and in combination with vincristine and temozolomide, for children with refractory or relapsed solid tumors. The study is divided into two phases: Phase 1 focuses on determining the recommended dose of PEEL-224, while Phase 2 assesses the overall response rate in children with neuroblastoma and rhabdomyosarcoma. Participants will undergo treatment cycles and be monitored for disease response and side effects throughout the study duration.

Who should consider this trial

Good fit: Ideal candidates are children aged 1 to 18 years with refractory or relapsed solid tumors who have received prior therapy.

Not a fit: Patients with non-solid tumors or those who have not received any prior treatment may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for children with difficult-to-treat solid tumors.

How similar studies have performed: Other studies have shown promise in using combination therapies for similar pediatric solid tumors, suggesting potential for success in this approach.

Eligibility criteria

Inclusion Criteria:

1. Age:

   * Phase 1: Age greater than or equal to 1 year and less than or equal to18 years
   * Phase 2 Neuroblastoma (NBL) cohort: Age greater than or equal to 1 year and less than or equal to 30 years
   * Phase 2 Rhabdomyosarcoma (RMS) cohort: Age greater than or equal to 1 year and less than or equal to18 years
2. Diagnosis of:

   * Phase 1: Refractory, progressive or relapsed non-central nervous system (CNS) solid tumors who have received at least 1 line of upfront therapy. Patients must have had histologic verification of their malignancy at original diagnosis or relapse
   * Phase 2: Refractory, progressive or relapsed neuroblastoma (NBL) or rhabdomyosarcoma (RMS) who have received at least 1 line of upfront therapy. Patients must have had histologic verification of their malignancy at original diagnosis or relapse.
3. Disease status:

   * Phase 1: evaluable or measurable disease
   * Phase 2, subjects with Neuroblastoma (NBL): evaluable or measurable disease by International Neuroblastoma Response Criteria (INRC); subjects with only bone marrow disease are not eligible
   * Phase 2, subjects with rhabdomyosarcoma (RMS): measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)1.1.
4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 (age greater than 16 years) or Lansky Performance Status of at least 60 (age less than 16 years).
5. Females of childbearing potential must have a negative urine/serum pregnancy test.
6. Adequate bone marrow function

   Hematologic requirements for all subjects on phase 1 and subjects on phase 2 without malignant infiltration of the bone marrow:
   * Absolute neutrophil count (ANC) greater than or equal to 750/mm3 (greater than or equal to 7 days since last dose of short acting myeloid growth factor medications (e.g. filgrastim) and greater than or equal to 14 days since last dose of long-acting myeloid medications (e.g. peg-filgrastim)
   * Platelet count ≥ 75,000 mm3 (greater than or equal to 14 days since last dose of thrombopoietin receptor agonist such as romiplostim and without platelet transfusion within previous 7 days)
   * Not refractory to packed red blood cell transfusions

   Hematologic requirements for subjects on phase 2 with malignant infiltration of the bone marrow:
   * Absolute neutrophil count (ANC) greater than or equal to 500/mm3 (greater than or equal to 7 days since last dose of short acting myeloid growth factor medications (e.g. filgrastim) and greater than or equal to 14 days since last dose of long-acting myeloid medications (e.g. peg-filgrastim))
   * Platelet count greater than or equal to 50,000/mm3 (greater than or equal to 14 days since last dose of thrombopoietin receptor agonist such as romiplostim and without platelet transfusion within previous 7 days)
   * Not refractory to packed red blood cell transfusions
   * Patients on phase 2 with malignant infiltration of the bone marrow will not be evaluable for hematologic toxicity.
7. Adequate renal function as evidenced by creatinine clearance as calculated by the Schwartz equation (see below), radioisotope glomerular filtration rate (GFR) greater than or equal to 70 mL/min/1.73 m2, or maximum serum creatinine as below:

   Age Maximum Serum Creatinine (mg/dL)

   Male Female 1 to less than 2 years 0.6 0.6 2 to less than 6 years 0.8 0.8 6 to less than 10 years 1 1 10 to less than 13 years 1.2 1.2 13 to less than 16 years 1.5 1.4 greater than 16 years 1.7 1.4 Threshold derived from the Schwartz formula for estimating glomerular filtration rate (GFR) (Schwartz et al., J.Peds, 106:522,1985) utilizing child length and stature data published by the CDC The Schwartz equation for subjects less than 18 years of age: eGFR (mL/min/1.73 m2) = 0.413 x \[height (cm)/serum creatinine (mg/dL)\]
8. Adequate liver function

   * Aspartate Aminotransferase (AST/SGOT): less than or equal to 3 times the upper limit of normal (ULN) or less than or equal to 5 the upper limit of normal if attributable to disease involvement. For the purpose of this study, the upper limit of normal (ULN) for Aspartate Aminotransferase (AST) is 50 U/L.
   * Alanine Aminotransferase (ALT/SGPT): less than or equal to 3 times the ULN or less than or equal to 5 the upper limit of normal if attributable to disease involvement. For the purpose of this study, the upper limit of normal (ULN) for Alanine Aminotransferase (ALT) is 45 U/L.
   * Total bilirubin: less than or equal to 1.5 times the upper limit of normal with the exception of patients with Gilbert's syndrome who must have bilirubin less than 3X institutional upper limit of normal (ULN).
9. Prior Therapy: Patients must have had resolution of acute toxic effects of prior therapy to grade less than or equal to 1 according to the National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) v 5.0 except organ function as noted above, adverse events (AE) that are considered clinically non-significant (i.e. alopecia), or controlled on supportive care (i.e. nausea/vomiting, hypothyroidism). Patients must meet the following minimum washout periods prior to enrollment:

   * Myelosuppressive chemotherapy: At least 14 days after the last dose of myelosuppressive chemotherapy
   * Small molecule targeted therapy: At least 7 days following the last dose of a small molecule targeted agent.
   * Antibody therapy: At least 21 days following the last dose of antibody including anti-GD2 monoclonal antibody.
   * Cellular therapy: At least 42 days following completion of a cellular therapy agent (e.g. modified T cells, NK cells, dendritic cells)
   * Autologous hematopoietic stem cell transplant and stem cell boost: Subjects must be at least 60 days from day 0 of an autologous stem cell transplant or stem cell boost.
   * Myeloid growth factors: At least 7 days following short-acting myeloid growth factor (e.g. filgrastim) and at least 14 days following the last dose of long-acting myeloid growth factor (e.g. peg-filgrastim)
   * Thrombopoietin receptor agonists: At least 14 days following last dose of thrombopoietin receptor agonist such as romiplostim
   * Interleukins, interferons, and cytokines (other than hematopoietic growth factors): At least 21 days following the completion of interleukins, interferon, or cytokines, including IL-2
   * Radiotherapy:

     * At least 14 days after limited field radiation therapy;
     * At least 90 days after total body irradiation, craniospinal radiotherapy; or radiation to greater than 50% of pelvis;
     * At least 42 days must have elapsed if other substantial BM radiation.
   * Radiopharmaceutical therapy (e.g. radiolabeled antibody, 131I- MIBG): At least 42 days after radiopharmaceutical therapy
   * Major Surgery: At least 2 weeks from prior major surgical procedure. Note: Biopsy, CNS shunt placement/revision, and central line placement/removal are not considered major.
   * Strong CYP1A2 and/or CYP3A4 inhibitors and/or inducers: At least 14 days following use of a strong CYP1A2 and/or CYP3A4 inhibitor and/or inducer. See Appendix 1 for examples. (Note that levofloxacin is permitted when clinically indicated)
10. Prior treatment with irinotecan and/or temozolomide is permitted.
11. Female patients of reproductive potential must agree to use a highly effective contraceptive method for the duration of study therapy and for at least six months after the final dose of PEEL-224. Males of reproductive potential with a female partner of child-bearing potential must use a highly effective for the duration of the study and for at least six months after the final dose of PEEL-224.
12. Subjects must agree to use sun protective measures while receiving treatment and for 4 weeks after the last dose of PEEL-224
13. Parental/guardian permission (informed consent) and if appropriate, child assent.

Exclusion Criteria:

1. Prior treatment with PEEL-224.
2. Subjects receiving any other anti-cancer agents.
3. Subjects with primary central nervous system (CNS) solid tumors or central nervous system (CNS) metastatic disease.
4. Subjects with prior allogeneic stem cell or solid organ transplantation.
5. Pregnant or lactating females.
6. Subjects with a known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C (testing not required as part of screening).
7. Subjects with symptomatic congestive heart failure.

Where this trial is running

Los Angeles, California and 6 other locations

• Cedars-Sinai Medical Center — Los Angeles, California, United States (Not_yet_recruiting)
• University of California, San Francisco — San Francisco, California, United States (Not_yet_recruiting)
• Boston Children's Hospital — Boston, Massachusetts, United States (Not_yet_recruiting)
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States (Not_yet_recruiting)
• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States (Recruiting)
• Texas Children's Hospital — Houston, Texas, United States (Not_yet_recruiting)
• University of Utah Hospital — Salt Lake City, Utah, United States (Not_yet_recruiting)

Study contacts

• Principal investigator: Jacquelyn Crane, MD — Children's Hospital of Philadelphia
• Study coordinator: Meghan Donnelly, MPH

Conditions Refractory Solid Tumors; Relapsed Solid Tumors; Relapsed Neuroblastoma; Refractory Neuroblastoma; Relapsed Rhabdomyosarcoma; Refractory Rhabdomyosarcoma; Relapsed; Refractory